Walmark, a Mid Europa Partners portfolio company, acquires Czech probiotic developer Valosun

Walmark a.s., a major Consumer Healthcare player in Central and Eastern Europe with a leading position in food supplements, has announced that it has further expanded its portfolio in the Czech Republic and in Slovakia by acquiring Valosun a.s. (“Valosun“).  Mid Europa Partners has been an investor in Walmark since late 2012.

Valosun is the leading Probiotic player in the Czech Republic and Slovakia with the brand Biopron and holds a significant market position in Female Urinal Health with Uroval. This will respectively extend Walmark’s presence in Digestive Health and substantially strengthen the Company’s position in Female Urinary Health. Valosun also holds a privileged position with Czech and Slovak Healthcare Professionals alike.

Jorge C. Manuel, the CEO of Walmark commented: “We are delighted to add Valosun’s brands, team and medical expertise to our portfolio of valued assets, which will complement our existing presence in two key growth categories and further strengthen our position in the key Czech and Slovak markets.”

Robert Chmelar, Director at Mid Europa, added: “The acquisition of Valosun is the second transaction executed by the Walmark team this year, in line with the Company’s long term ambitious strategy of organic and acquisitive growth. We are currently pursuing a number of additional potential acquisitions across Central and Eastern Europe.”

Walmark was advised by Patria, White & Case and Deloitte.

Viktoria Habanova and Tomas Vrba from Mid Europa supported Walmark’s management in executing the transaction.

 

Source: Mid Europa Partners Press Release

Email this to someoneShare on LinkedInShare on FacebookTweet about this on TwitterShare on Google+